Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Tan

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Nanotechnology|September 21, 2018
Solution blow spinning (SBS)-assisted synthesis of well-defined carboxymethyl cellulose (CMC) nanowhiskersJames Matthew Salva, Dale Daryl Gutierrez, Lorraine Ann Ching, et al.
Phlebology|June 14, 2013
Day-case re-do varicose vein surgeryKamal Nagpal, R J Glore, Peter Lee Chong, et al.
British Journal of Haematology|February 4, 2015
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemiaAndrew Wei, Peter Tan, Sarah Perruzza, et al.
Oncotarget|September 9, 2017
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II studyPeter Tan, Ing Soo Tiong, Shaun Fleming, et al.
Journal of Hematology & Oncology|May 29, 2026
A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignanciesLi Wang, Jiaying Liu, Keshu Zhou, et al.
Leukemia Research|March 2, 2018
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift studyDevendra Hiwase, Peter Tan, James D'Rozario, et al.
International Journal of Molecular Sciences|November 11, 2022
Nontoxic and Naturally Occurring Active Compounds as Potential Inhibitors of Biological Targets in <i>Liriomyza trifolii</i>Israa M Shamkh, Mohammed Al-Majidi, Ahmed Hassen Shntaif, et al.
Platelets|November 2, 2017
Diagnosis and treatment of <i>MYH9-</i>RD in an Australasian cohort with thrombocytopeniaDavid J Rabbolini, Yenna Chun, Maya Latimer, et al.
Blood Advances|January 28, 2025
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APLHarry J Iland, John Reynolds, Alan V Boddy, et al.
Haematologica|April 17, 2025
A phase I / IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosisPankit Vachhani, Peter Tan, Anne-Marie Watson, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Nanotechnology|September 21, 2018
Solution blow spinning (SBS)-assisted synthesis of well-defined carboxymethyl cellulose (CMC) nanowhiskersJames Matthew Salva, Dale Daryl Gutierrez, Lorraine Ann Ching, et al.
Phlebology|June 14, 2013
Day-case re-do varicose vein surgeryKamal Nagpal, R J Glore, Peter Lee Chong, et al.
British Journal of Haematology|February 4, 2015
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemiaAndrew Wei, Peter Tan, Sarah Perruzza, et al.
Oncotarget|September 9, 2017
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II studyPeter Tan, Ing Soo Tiong, Shaun Fleming, et al.
Journal of Hematology & Oncology|May 29, 2026
A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignanciesLi Wang, Jiaying Liu, Keshu Zhou, et al.
Leukemia Research|March 2, 2018
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift studyDevendra Hiwase, Peter Tan, James D'Rozario, et al.
International Journal of Molecular Sciences|November 11, 2022
Nontoxic and Naturally Occurring Active Compounds as Potential Inhibitors of Biological Targets in <i>Liriomyza trifolii</i>Israa M Shamkh, Mohammed Al-Majidi, Ahmed Hassen Shntaif, et al.
Platelets|November 2, 2017
Diagnosis and treatment of <i>MYH9-</i>RD in an Australasian cohort with thrombocytopeniaDavid J Rabbolini, Yenna Chun, Maya Latimer, et al.
Blood Advances|January 28, 2025
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APLHarry J Iland, John Reynolds, Alan V Boddy, et al.
Haematologica|April 17, 2025
A phase I / IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosisPankit Vachhani, Peter Tan, Anne-Marie Watson, et al.
Pageof 3